Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$2.65 - $3.81 $113,027 - $162,504
42,652 Added 20.75%
248,207 $737,000
Q4 2022

Feb 14, 2023

BUY
$3.38 - $4.22 $84,577 - $105,597
25,023 Added 13.86%
205,555 $750,000
Q3 2022

Nov 14, 2022

SELL
$3.43 - $5.83 $50,764 - $86,284
-14,800 Reduced 7.58%
180,532 $649,000
Q2 2022

Aug 12, 2022

BUY
$4.41 - $5.69 $54,071 - $69,765
12,261 Added 6.7%
195,332 $1.03 Million
Q2 2021

Aug 16, 2021

BUY
$5.35 - $6.35 $63,969 - $75,926
11,957 Added 6.99%
183,071 $1.08 Million
Q1 2021

May 14, 2021

SELL
$5.68 - $7.87 $79,764 - $110,518
-14,043 Reduced 7.58%
171,114 $1.03 Million
Q4 2020

Mar 01, 2021

SELL
$5.25 - $8.56 $103,619 - $168,948
-19,737 Reduced 9.63%
185,157 $1.28 Million
Q3 2020

Nov 13, 2020

BUY
$5.78 - $7.47 $79,925 - $103,295
13,828 Added 7.24%
204,894 $1.28 Million
Q2 2020

Aug 14, 2020

BUY
$4.5 - $7.02 $191,776 - $299,171
42,617 Added 28.71%
191,066 $1.26 Million
Q1 2020

May 15, 2020

BUY
$2.87 - $5.49 $157,310 - $300,917
54,812 Added 58.54%
148,449 $690,000
Q4 2019

Feb 14, 2020

SELL
$3.84 - $4.86 $26,649 - $33,728
-6,940 Reduced 6.9%
93,637 $395,000
Q3 2019

Nov 14, 2019

BUY
$4.86 - $6.05 $83,898 - $104,441
17,263 Added 20.72%
100,577 $518,000
Q2 2019

Aug 15, 2019

SELL
$4.51 - $6.6 $11,347 - $16,605
-2,516 Reduced 2.93%
83,314 $0
Q1 2019

May 14, 2019

BUY
$5.16 - $6.85 $109,541 - $145,418
21,229 Added 32.86%
85,830 $0
Q2 2018

Aug 14, 2018

SELL
$5.19 - $7.25 $111,600 - $155,896
-21,503 Reduced 24.97%
64,601 $0
Q1 2018

May 14, 2018

BUY
$3.56 - $5.74 $129,929 - $209,492
36,497 Added 73.57%
86,104 $0
Q3 2017

Nov 13, 2017

BUY
$2.22 - $2.73 $110,127 - $135,427
49,607
49,607 $0

Others Institutions Holding CERS

About CERUS CORP


  • Ticker CERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 177,090,000
  • Market Cap $375M
  • Description
  • Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...
More about CERS
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.